Tissue Engineering Market Report by Type, Application, End User, and Region 2025-2033
¼¼°èÀÇ Á¶Á÷°øÇÐ ½ÃÀå ½ÃÀå ±Ô¸ð´Â 2024³â¿¡ 200¾ï ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÇâÈÄ IMARC GroupÀº ½ÃÀåÀÌ 2033³â±îÁö 510¾ï ´Þ·¯¿¡ ´ÞÇϸç, 2025-2033³â¿¡ 10.9%ÀÇ ¼ºÀå·ü(CAGR)À» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ ½ÃÀåÀ» ÃËÁøÇÏ´Â °ÍÀº Àç»ýÀÇ·á ¹× TE¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ±³Åë»ç°í ¹× ¿Ü»óÀ¸·Î ÀÎÇÑ »ç¸Á»ç°í Áõ°¡, ȯÀÚÀÇ »À ÀÓÇöõÆ® ¼ö¿ä Áõ°¡, 3Â÷¿ø(3D) Á¶Á÷°øÇÐ ºÐ¾ßÀÇ Áö¼ÓÀûÀÎ ±â¼ú ¹ßÀü, ÀÇ·áºñ ÁöÃâ Áõ°¡ µîÀÔ´Ï´Ù.
Á¶Á÷°øÇÐ(TE)Àº ¼¼Æ÷, ½ºÄ³Æúµå, »ý¹°ÇÐÀû Ȱ¼º ºÐÀÚ¸¦ °áÇÕÇÏ¿© ±â´ÉÀûÀÎ Á¶Á÷À» ¸¸µå´Â »ýÀÇÇÐ °øÇÐÀÇ ÇÑ ºÐ¾ßÀÔ´Ï´Ù. »ý¸í°úÇаú °øÇÐÀÇ ¿ø¸®¸¦ Àû¿ëÇÏ¿© ´Ù¾çÇÑ À¯ÇüÀÇ Á¶Á÷°ú Àå±â¸¦ ȸº¹, °³¼±, À¯Áö, ´ëüÇÒ ¼ö ÀÖ´Â »ý¹°ÇÐÀû ´ëü¹°À» °³¹ßÇÕ´Ï´Ù. ¼Õ»óµÈ Á¶Á÷À» º¹±¸Çϱâ À§ÇØ »ç¿ëµÇ´Â À̽Ä, ¿Ü°úÀû Àç°Ç¼ú ¹× ±âŸ ±â°èÀû Àåºñ¿¡ ´ëÇÑ È¿À²ÀûÀÎ ´ë¾ÈÀ» Á¦°øÇÕ´Ï´Ù. ±× °á°ú, Á¶Á÷°øÇÐÀº È»ó Ä¡·á, ½Å°æÇÐ, »óó Ä¡·á, Á¤Çü¿Ü°ú, ±Ù°ñ°Ý°è, ½ÉÇ÷°ü°è, ºñ´¢±â°ú µî ´Ù¾çÇÑ ÀÇ·á ºÐ¾ß¿¡¼ ºü¸£°Ô È®»êµÇ°í ÀÖ½À´Ï´Ù. ÇöÀç ¿¬±¸ÀÚµéÀº ºñ±³Àû Àú·ÅÇÏ°í ½±°Ô ±¸ÇÒ ¼ö ÀÖ´Â ÇǺΠ´ëü Á¦Ç°¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ ´ëÀÀÇϱâ À§ÇØ ÇǺΠ´ëü¿ë ¹ÙÀÌ¿À¼ÒÀç °³¹ß¿¡ ÁýÁßÇϰí ÀÖ½À´Ï´Ù.
Á¶Á÷°øÇÐ ½ÃÀå µ¿Çâ :
Á¶Á÷°øÇÐ ½Ã¼úÀº Á¶Á÷ÀÇ ºñ°¡¿ªÀû ¼Õ»óÀ» Ä¡·áÇÏ´Â µ¥ È¿°úÀûÀÓÀÌ ÀÔÁõµÇ¾ú½À´Ï´Ù. ÀÌ¿¡ µû¶ó Àç»ýÀÇ·á ¹× Á¶Á÷°øÇÐ ½Ã¼ú¿¡ ´ëÇÑ ¼ö¿ä°¡ Å©°Ô Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÌ´Â ½ÃÀå ¼ºÀåÀ» À̲ô´Â ÁÖ¿ä ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ÀÌ ¿Ü¿¡µµ ±³Åë»ç°í ¹× ¿Ü»óÀ¸·Î ÀÎÇÑ »ç¸Á·ü Áõ°¡, ȯÀÚµé »çÀÌ¿¡¼ »À ÀÓÇöõÆ®¿¡ ´ëÇÑ ¿ä±¸°¡ Áõ°¡Çϰí ÀÖ´Â °Íµµ Á¦Ç° ¼ö¿ä¸¦ Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÁÂ½Ä »ýȰ, °í·ÉÈ, °Ç°¿¡ ÇØ·Î¿î ½Ä½À°üÀ¸·Î ÀÎÇØ ´ç´¢º´, ¾Ï, ºñ¸¸, ½ÉÇ÷°ü Áúȯ°ú °°Àº ¸¸¼ºÁúȯÀÌ ³Î¸® ÆÛÁ® ÀÖ´Â °Íµµ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ Àå±â Ĩ ±â¼ú, ¹è¾Æ ¼¼Æ÷¿Í Áٱ⼼Æ÷ÀÇ ´ëü, ü¿Ü ÀÓÇöõÆ®¸¦ È¿À²ÀûÀ¸·Î ¼³°èÇϱâ À§ÇÑ 3D ¹ÙÀÌ¿À ÇÁ¸°ÅÍÀÇ »ç¿ë µî 3Â÷¿ø(3D) Á¶Á÷ °øÇÐ ºÐ¾ßÀÇ ±â¼ú ¹ßÀüÀº ½ÃÀå¿¡ À¯¸®ÇÑ ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ ÀϺΠÁ¦Ç° Çõ½Å, ¿¬±¸°³¹ß(R&D) Ȱµ¿¿¡ ´ëÇÑ Á¤ºÎ ÀÚ±Ý ¹× ¹Î°£ ÅõÀÚ Áõ°¡´Â ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù. ÀÌ ¿Ü¿¡µµ Àΰø°üÀý ġȯ¼ú ¹× Àç°Ç¼ú Áõ°¡, ¼ÒºñÀÚÀÇ ÀÇ·áºñ ÁöÃâ Áõ°¡, ¼ºÇü ¼ö¼ú¿¡ ´ëÇÑ ¼ö¿ä ±ÞÁõ µîÀÌ ½ÃÀå Àü¸ÁÀ» ¹à°Ô Çϰí ÀÖ½À´Ï´Ù.
ÀÌ º¸°í¼¿¡¼ ´Ù·é ÁÖ¿ä Áú¹®
- 2024³â ¼¼°è Á¶Á÷°øÇÐ ½ÃÀå ±Ô¸ð´Â?
- 2025-2033³â ¼¼°è Á¶Á÷°øÇÐ ½ÃÀå ¼ºÀå·üÀº?
- ¼¼°è Á¶Á÷°øÇÐ ½ÃÀåÀ» ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎÀº?
- COVID-19°¡ ¼¼°è Á¶Á÷°øÇÐ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀº?
- ¼¼°è Á¶Á÷°øÇÐ ½ÃÀåÀÇ À¯Çüº° ºÐ·ù´Â?
- ¼¼°è Á¶Á÷°øÇÐ ½ÃÀåÀÇ ¿ëµµº° ½ÃÀå ÇöȲÀº?
- ¼¼°è Á¶Á÷°øÇÐ ½ÃÀåÀÇ ÁÖ¿ä Áö¿ªÀº?
- ¼¼°è Á¶Á÷°øÇÐ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷Àº?
¸ñÂ÷
Á¦1Àå ¼¹®
Á¦2Àå Á¶»ç ¹üÀ§¿Í Á¶»ç ¹æ¹ý
- Á¶»çÀÇ ¸ñÀû
- ÀÌÇØ°ü°èÀÚ
- µ¥ÀÌÅÍ ¼Ò½º
- ½ÃÀå ÃßÁ¤
- º¸ÅÒ¾÷ ¾îÇÁ·ÎÄ¡
- Åé´Ù¿î ¾îÇÁ·ÎÄ¡
- Á¶»ç ¹æ¹ý
Á¦3Àå °³¿ä
Á¦4Àå ¼·Ð
Á¦5Àå ¼¼°èÀÇ Á¶Á÷°øÇÐ ½ÃÀå
- ½ÃÀå °³¿ä
- ½ÃÀå ½ÇÀû
- COVID-19ÀÇ ¿µÇâ
- ½ÃÀå ¿¹Ãø
Á¦6Àå ½ÃÀå ³»¿ª : À¯Çüº°
- ÇÕ¼º ½ºÄ³Æúµå Àç·á
- »ý¹° À¯·¡ ½ºÄ³Æúµå Àç·á
- ±âŸ
Á¦7Àå ½ÃÀå ³»¿ª : ¿ëµµº°
- Á¤Çü¿Ü°ú¡¤±Ù°ñ°Ý°è
- ½Å°æ°è
- ½ÉÇ÷°ü°è
- ÇǺΡ¤¿ÜÇǰè
- Ä¡°ú°è
- ±âŸ
Á¦8Àå ½ÃÀå ³»¿ª : ÃÖÁ¾»ç¿ëÀÚº°
Á¦9Àå ½ÃÀå ³»¿ª : Áö¿ªº°
- ºÏ¹Ì
- ¾Æ½Ã¾ÆÅÂÆò¾ç
- Áß±¹
- ÀϺ»
- Àεµ
- Çѱ¹
- È£ÁÖ
- Àεµ³×½Ã¾Æ
- ±âŸ
- À¯·´
- µ¶ÀÏ
- ÇÁ¶û½º
- ¿µ±¹
- ÀÌÅ»¸®¾Æ
- ½ºÆäÀÎ
- ·¯½Ã¾Æ
- ±âŸ
- ¶óƾ¾Æ¸Þ¸®Ä«
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
Á¦10Àå SWOT ºÐ¼®
Á¦11Àå ¹ë·ùüÀÎ ºÐ¼®
Á¦12Àå Porter's Five Forces ºÐ¼®
- °³¿ä
- ¹ÙÀ̾îÀÇ ±³¼··Â
- °ø±Þ ±â¾÷ÀÇ ±³¼··Â
- °æÀïÀÇ Á¤µµ
- ½Å±Ô ÁøÃâ¾÷üÀÇ À§Çù
- ´ëüǰÀÇ À§Çù
Á¦13Àå °¡°Ý ºÐ¼®
Á¦14Àå °æÀï ±¸µµ
- ½ÃÀå ±¸Á¶
- ÁÖ¿ä ±â¾÷
- ÁÖ¿ä ±â¾÷ÀÇ °³¿ä
- AbbVie Inc.
- B. Braun Melsungen AG
- Baxter International Inc
- Becton, Dickinson and Company
- Integra LifeSciences Corporation
- Organogenesis Holdings Inc
- RTI Surgical
- Smith & Nephew plc
- Stryker Corporation
- Vericel Corporation
- Zimmer Biomet
KSA
The global tissue engineering market size reached USD 20.0 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 51.0 Billion by 2033, exhibiting a growth rate (CAGR) of 10.9% during 2025-2033. The market is driven by the increasing demand for regenerative medicines and TE procedures, rising incidences of fatal road accidents and trauma injuries, the augmenting need for bone implants among patients, continual technological advancements in the field of three-dimensional (3D) tissue engineering, and rising healthcare expenditure.
Tissue engineering (TE) is a biomedical engineering discipline that combines cells, scaffolds, and biologically active molecules into functional tissues. It applies the principles of life sciences and engineering to develop biological substitutes to restore, improve, maintain, or replace different types of tissues or organs. It provides efficient alternatives to transplants, surgical reconstruction procedures, and other mechanical devices that are used to repair damaged tissues. As a result, tissue engineering is rapidly gaining traction in numerous medical applications, including burn treatment, neurology, wound care, orthopedic, musculoskeletal, cardiovascular, and urological products. Nowadays, researchers are focusing on developing biomaterials for skin substitution to meet the growing demand for relatively cheaper and easily available skin replacement products.
Tissue Engineering Market Trends:
Tissue engineering procedures have proven effective in treating irreversible damage to tissues. This has led to a significant increase in the demand for regenerative medicines and TE procedures, which represents the primary factor driving the market growth. Besides this, the rising incidences of fatal road accidents and trauma injuries, along with the growing need for bone implants among patients, are augmenting the product demand. Additionally, the widespread prevalence of chronic diseases, such as diabetes, cancer, obesity and cardiovascular disorders, due to sedentary lifestyle habits, aging population and unhealthy diets, is catalyzing the market growth. Furthermore, technological advancements in the field of three-dimensional (3D) tissue engineering, such as organ-on-a-chip technology, replacement of embryo cells with stem cells, and use of 3D bioprinters to design in vitro implants efficiently, are offering lucrative opportunities to the market. Moreover, several product innovations, and the increasing government funding and private investments in research and development (R&D) activities are propelling the market growth. Other factors, including the growing number of replacements and reconstructive surgeries, rising consumer healthcare expenditure, and surging demand for plastic surgeries, are also creating a positive market outlook.
Key Market Segmentation:
Breakup by Type:
- Synthetic Scaffold Material
- Biologically Derived Scaffold Material
- Others
Breakup by Application:
- Orthopedics and Musculoskeletal
- Neurology
- Cardiovascular
- Skin and Integumentary
- Dental
- Others
Breakup by End User:
- Hospitals and Clinics
- Ambulatory Facilities
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being AbbVie Inc., B. Braun Melsungen AG, Baxter International Inc, Becton, Dickinson and Company, Integra LifeSciences Corporation, Organogenesis Holdings Inc, RTI Surgical, Smith & Nephew plc, Stryker Corporation, Vericel Corporation and Zimmer Biomet.
Key Questions Answered in This Report
- 1.What was the size of the global tissue engineering market in 2024?
- 2.What is the expected growth rate of the global tissue engineering market during 2025-2033?
- 3.What are the key factors driving the global tissue engineering market?
- 4.What has been the impact of COVID-19 on the global tissue engineering market?
- 5.What is the breakup of the global tissue engineering market based on the type?
- 6.What is the breakup of the global tissue engineering market based on the application?
- 7.What are the key regions in the global tissue engineering market?
- 8.Who are the key players/companies in the global tissue engineering market?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Tissue Engineering Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Type
- 6.1 Synthetic Scaffold Material
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Biologically Derived Scaffold Material
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Others
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
7 Market Breakup by Application
- 7.1 Orthopedics and Musculoskeletal
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Neurology
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Cardiovascular
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 7.4 Skin and Integumentary
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
- 7.5 Dental
- 7.5.1 Market Trends
- 7.5.2 Market Forecast
- 7.6 Others
- 7.6.1 Market Trends
- 7.6.2 Market Forecast
8 Market Breakup by End User
- 8.1 Hospitals and Clinics
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Ambulatory Facilities
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
9 Market Breakup by Region
- 9.1 North America
- 9.1.1 United States
- 9.1.1.1 Market Trends
- 9.1.1.2 Market Forecast
- 9.1.2 Canada
- 9.1.2.1 Market Trends
- 9.1.2.2 Market Forecast
- 9.2 Asia-Pacific
- 9.2.1 China
- 9.2.1.1 Market Trends
- 9.2.1.2 Market Forecast
- 9.2.2 Japan
- 9.2.2.1 Market Trends
- 9.2.2.2 Market Forecast
- 9.2.3 India
- 9.2.3.1 Market Trends
- 9.2.3.2 Market Forecast
- 9.2.4 South Korea
- 9.2.4.1 Market Trends
- 9.2.4.2 Market Forecast
- 9.2.5 Australia
- 9.2.5.1 Market Trends
- 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
- 9.2.6.1 Market Trends
- 9.2.6.2 Market Forecast
- 9.2.7 Others
- 9.2.7.1 Market Trends
- 9.2.7.2 Market Forecast
- 9.3 Europe
- 9.3.1 Germany
- 9.3.1.1 Market Trends
- 9.3.1.2 Market Forecast
- 9.3.2 France
- 9.3.2.1 Market Trends
- 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
- 9.3.3.1 Market Trends
- 9.3.3.2 Market Forecast
- 9.3.4 Italy
- 9.3.4.1 Market Trends
- 9.3.4.2 Market Forecast
- 9.3.5 Spain
- 9.3.5.1 Market Trends
- 9.3.5.2 Market Forecast
- 9.3.6 Russia
- 9.3.6.1 Market Trends
- 9.3.6.2 Market Forecast
- 9.3.7 Others
- 9.3.7.1 Market Trends
- 9.3.7.2 Market Forecast
- 9.4 Latin America
- 9.4.1 Brazil
- 9.4.1.1 Market Trends
- 9.4.1.2 Market Forecast
- 9.4.2 Mexico
- 9.4.2.1 Market Trends
- 9.4.2.2 Market Forecast
- 9.4.3 Others
- 9.4.3.1 Market Trends
- 9.4.3.2 Market Forecast
- 9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast
10 SWOT Analysis
- 10.1 Overview
- 10.2 Strengths
- 10.3 Weaknesses
- 10.4 Opportunities
- 10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
- 12.1 Overview
- 12.2 Bargaining Power of Buyers
- 12.3 Bargaining Power of Suppliers
- 12.4 Degree of Competition
- 12.5 Threat of New Entrants
- 12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
- 14.1 Market Structure
- 14.2 Key Players
- 14.3 Profiles of Key Players
- 14.3.1 AbbVie Inc.
- 14.3.1.1 Company Overview
- 14.3.1.2 Product Portfolio
- 14.3.1.3 Financials
- 14.3.1.4 SWOT Analysis
- 14.3.2 B. Braun Melsungen AG
- 14.3.2.1 Company Overview
- 14.3.2.2 Product Portfolio
- 14.3.2.3 SWOT Analysis
- 14.3.3 Baxter International Inc
- 14.3.3.1 Company Overview
- 14.3.3.2 Product Portfolio
- 14.3.3.3 Financials
- 14.3.3.4 SWOT Analysis
- 14.3.4 Becton, Dickinson and Company
- 14.3.4.1 Company Overview
- 14.3.4.2 Product Portfolio
- 14.3.4.3 Financials
- 14.3.4.4 SWOT Analysis
- 14.3.5 Integra LifeSciences Corporation
- 14.3.5.1 Company Overview
- 14.3.5.2 Product Portfolio
- 14.3.5.3 Financials
- 14.3.5.4 SWOT Analysis
- 14.3.6 Organogenesis Holdings Inc
- 14.3.6.1 Company Overview
- 14.3.6.2 Product Portfolio
- 14.3.6.3 Financials
- 14.3.7 RTI Surgical
- 14.3.7.1 Company Overview
- 14.3.7.2 Product Portfolio
- 14.3.8 Smith & Nephew plc
- 14.3.8.1 Company Overview
- 14.3.8.2 Product Portfolio
- 14.3.8.3 Financials
- 14.3.8.4 SWOT Analysis
- 14.3.9 Stryker Corporation
- 14.3.9.1 Company Overview
- 14.3.9.2 Product Portfolio
- 14.3.9.3 Financials
- 14.3.9.4 SWOT Analysis
- 14.3.10 Vericel Corporation
- 14.3.10.1 Company Overview
- 14.3.10.2 Product Portfolio
- 14.3.10.3 Financials
- 14.3.10.4 SWOT Analysis
- 14.3.11 Zimmer Biomet
- 14.3.11.1 Company Overview
- 14.3.11.2 Product Portfolio
- 14.3.11.3 Financials
- 14.3.11.4 SWOT Analysis